RANI
Income statement / Annual
Last year (2024), Rani Therapeutics Holdings, Inc.'s total revenue was $1.03 M,
and the percentage change from the previous year is not available.
In 2024, Rani Therapeutics Holdings, Inc.'s net income was -$30.02 M.
See Rani Therapeutics Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$1.03 M |
$0.00 |
$0.00 |
$2.72 M |
$462.00 K |
$979.00 K |
| Cost of Revenue |
$0.00
|
$822.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$1.03 M
|
-$822.00 K
|
$0.00
|
$2.72 M
|
$462.00 K
|
$979.00 K
|
| Gross Profit Ratio |
1
|
0
|
0
|
1
|
1
|
1
|
| Research and Development Expenses |
$26.68 M
|
$39.62 M
|
$36.61 M
|
$26.48 M
|
$12.04 M
|
$24.58 M
|
| General & Administrative Expenses |
$23.95 M
|
$26.48 M
|
$26.84 M
|
$27.83 M
|
$4.96 M
|
$3.47 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$23.95 M
|
$26.48 M
|
$26.84 M
|
$27.83 M
|
$4.96 M
|
$3.47 M
|
| Other Expenses |
$3.71 M
|
-$822.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$54.34 M
|
$65.28 M
|
$63.45 M
|
$54.32 M
|
$17.01 M
|
$28.04 M
|
| Cost And Expenses |
$54.34 M
|
$66.10 M
|
$63.45 M
|
$54.32 M
|
$17.01 M
|
$28.04 M
|
| Interest Income |
$1.76 M
|
$3.30 M
|
$1.25 M
|
$89.00 K
|
$63.00 K
|
$423.00 K
|
| Interest Expense |
$5.03 M
|
$5.09 M
|
$1.07 M
|
$466.00 K
|
$124.00 K
|
$10.00 K
|
| Depreciation & Amortization |
$1.03 M
|
$822.00 K
|
$548.00 K
|
$497.00 K
|
$589.00 K
|
$564.00 K
|
| EBITDA |
-$50.52 M |
-$65.28 M |
-$61.66 M |
-$52.08 M |
-$15.96 M |
-$26.01 M |
| EBITDA Ratio |
-49.15
|
0
|
0
|
-19.17
|
-34.53
|
-26.57
|
| Operating Income Ratio |
-51.86
|
0
|
0
|
-18.99
|
-35.81
|
-27.65
|
| Total Other Income/Expenses Net |
$23.30 M
|
-$1.78 M
|
$177.00 K
|
-$1.45 M
|
-$124.00 K
|
$478.00 K
|
| Income Before Tax |
-$30.02 M
|
-$67.88 M
|
-$63.27 M
|
-$53.05 M
|
-$16.67 M
|
-$26.59 M
|
| Income Before Tax Ratio |
-29.2
|
0
|
0
|
-19.52
|
-36.08
|
-27.16
|
| Income Tax Expense |
$26.57 M
|
$0.00
|
$70.00 K
|
$41.00 K
|
$35.00 K
|
$0.00
|
| Net Income |
-$30.02 M
|
-$33.97 M
|
-$30.59 M
|
-$8.33 M
|
-$16.70 M
|
-$26.60 M
|
| Net Income Ratio |
-29.2
|
0
|
0
|
-3.07
|
-36.15
|
-27.17
|
| EPS |
-1.05 |
-1.33 |
-1.28 |
-0.42 |
-0.85 |
-1.35 |
| EPS Diluted |
-1.05 |
-1.33 |
-1.28 |
-0.42 |
-0.85 |
-1.35 |
| Weighted Average Shares Out |
$28.48 M
|
$25.51 M
|
$23.82 M
|
$19.53 M
|
$18.74 M
|
$18.74 M
|
| Weighted Average Shares Out Diluted |
$28.48 M
|
$25.51 M
|
$23.82 M
|
$19.53 M
|
$18.74 M
|
$18.74 M
|
| Link |
|
|
|
|
|
|
